Norwegian Cancer Society - National Group of Expertise for Research on Pancreatic Cancer (KNEP)

The National Group of Expertise on Pancreatic Cancer Research (KNEP) consists of nine research groups from Oslo, Bergen and Stavanger. Through a joint 5-years project supported by the Norwegian Cancer Society, the groups have bundled their research activities to improve early diagnostics and treatment of pancreatic cancer.


The aim of the project

The aim of our project is to stimulate collaboration across disciplines and institutions, and to join experts in the field of pancreatic cancer in order to strengthen research on this disease. The research groups will exchange data and biomaterials so that complex associations between various aspects of pancreatic cancer can be identified at the individual patient level. We seek to achieve much-needed, concrete progress in the management of pancreatic cancer patients. Through its collaborative network, KNEP will establish a competitive and sustainable research environment for pancreatic cancer in Norway.

Work packages

The consortium comprises the following nine work packages

Key Research Areas

The research portfolio of KNEP comprises studies in the central clinical fields of



Medical Genetics

In addition to laboratory studies on:

Multi-omics characterization of tumor tissue

High-throughput drug screening



Animal models for pancreatic cancer

The research groups are based in Oslo, Bergen, and Stavanger, and collaborate with patients from all over Norway. The University of Oslo is the host institution for this 5-years project.


Study period

May 2020 - April 2025

Our latest news

Stay informed about research and activities conducted by KNEP - the Norwegian Cancer Society’s National Group of Expertise on Pancreatic Cancer Research.


The results of a new study by the Pathology work package were presented at the annual meeting of the Norwegian Pathology Society. The study shows that pathology evaluation of the effect of neoadjuvant treatment of pancreatic cancer, is only reliable if tumour regression is extensive, while lesser degrees of treatment effect cannot be identified with certainty. Maia Blomhoff Holm (to the right on the photograph), who presented the study, was awarded the “Research prize 2024 – best free paper”. Read the publication here.


Stina M. Stålberg, MD, PhD student at Dept. of Cancer Genetics, ICR, Oslo University Hospital and USN (work package: “Omics and biomarkers”) presented a poster with results from a research project on protein levels of KRAS in pancreatic cancer at the Nordic Precision Cancer Medicine, Acta Oncologica Conference, Holmenkollen Park Hotel in Oslo, September 17-19, 2023.


Professor Oddmund Nordgård from Stavanger visited the Department of Pathology, Haukeland University hospital on January 10th. He gave a talk about his studies on circulating tumor DNA in pancreatic cancer. The presentation was very well received among the audience of more than 25 pathologists and molecular biologists, and was followed by a vivid discussion. Nordgård also had meetings with two research groups in Bergen to strengthen the collaborations between groups of the KNEP network.

Contact us

We will get back to you ASAP via email.